Development of Obsessive-Compulsive Behaviour
Following Cortisone Treatment

In this report, we will describe the first case of obsessive-compulsive behaviour following oral corticosteroid treatment in a 75-year old adult male patient with pulmonal disease, but without previous psychiatric symptoms or organic brain disorder. We will also discuss the clinical and pathophysiological considerations.

References

• 1 Bick P A. Single case study. Obsessive compulsive behaviour associated with dexamethasone treatment.  J Ner Ment Disease. 1983;  171 253-254
• 2 Chaouloff F. Regulation of 5-HT receptors by corticoids: Where do we stand?.  Fundam Clin Pharmacol. 1995;  9 219-233
• 3 Chouinard G, Belanger M C, Beauclair L, Sultan S, Murphy B E. Potentiation of fluoxetine by aminoglutethimide, an adrenal steroid suppressant, in obsessive-compulsive disorder resistant to SSRIs: a case report.  Prog Neuropsychopharmacol Biol Psychiatry. 1996;  6 1067-1079
• 4 Cinta A, Zoli M, Rosen L, Agnati L F, Okret S, Wikström A C, Gustafsson J A, Fuxe K. Mapping and computer assisted morphometry and microdensimetry of glucocorticoid receptor immunoreactive neurons and glial cells in the rat central nervous system.  Neuroscience. 1994;  62 843-897
• 5 Grabe H J, Freyberger H J, Maier W. Obsessive-Compulsive Symptom Exacerbation Following Cortisone Treatment.  Neuropsychobiol. 1998;  37 91-92
• 6 Jonasson G, Wilkinson S R. Prednisolon indusert obsessiv kompulsiv atferd hos barn.  Tidsskr Nor Laegeforen. 1993;  25 3162
• 7 Lanfumey L, Pardon M C, Laaris N, Joubert C, Homon M, Cohen-Salomon C. 5-HT_1A autoreceptor desensitization by chronic ultramild stress in mice.  Neuroreport. 1999;  16 3369-3374
• 8 Monteleone P, Catapano F, Tortorella A, Di Martino S, Maj M. Plasma melatonin and cortisol circadian patterns in patients with obsessive-compulsive disorder before and after fluoxetine treatment.  Psychoneuroendocrin. 1995;  20 763-770
• 9 Neill J D, Duck L W, Sellers J C, Musgrove L C, Scheschonka A, Druey K M, Kehrl J H. Potential role for a regulator of G protein signaling (RGS3) in gonadotropin-releasing hormone (GnRH) stimulated desensitisation.  Endocrinol. 1997;  138 843-846